Sub-optimal control of cardiovascular and renal comorbidities in diabetes continues to drive early morbidity and mortality. Emerging evidence shows that non-steroidal mineralocorticoid-receptor antagonists (MRAs) can curb inflammation and fibrosis across the heart–kidney continuum, offering additive protection beyond current guideline-directed therapy.

This 60-minute industry session—recorded live on 8 April 2025 at the IDF Congress in Bangkok—assembles international leaders to bridge knowledge gaps in diabetic kidney disease, outline new avenues to improve heart-failure outcomes, and translate the practical use of non-steroidal MRAs into everyday care.